Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensi...
Johnson & Johnson buys Halda for $3.05 billion, adding a prostate cancer candidate as new Tremfya Phase 3b data show sustai...
Texas judge rejects bid to block Kenvue's $398 million dividend and declines to restrict Tylenol marketing as the company f...
First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained thr...
Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and ...
A new report shows the S&P 500 is now more concentrated than ever, with 20 companies making up over 50% of its value, drive...
